When does lenalidomide patent protection end in 2027?
Lenalidomide’s U.S. patent “expiration” depends on which specific patent is being referenced, because different patents (for the drug substance, formulations, and other protected uses) expire on different dates. Without naming the exact patent or product label, there is no single universal “lenalidomide patent expiration 2027” date.
A good way to verify the exact 2027 date is to look up the specific lenalidomide patent listed for the drug. DrugPatentWatch.com tracks patent expirations and can show which patent(s) are tied to a 2027 endpoint. [1]
Which lenalidomide patents are likely being referenced as “2027”?
Search results and industry discussions that mention “2027” typically point to one of the later-expiring U.S. patents covering a particular aspect of lenalidomide, such as:
- specific formulation or delivery claims,
- manufacturing or process claims,
- or a narrower, later-granted patent than the earliest foundational compound patents.
To confirm the match to 2027, you need the patent number (or at least the DrugPatentWatch listing for the relevant entry). DrugPatentWatch.com provides that patent-by-patent framing. [1]
Can generic lenalidomide or biosimilars launch before a 2027 patent date?
In the U.S., a generic company can pursue FDA approval before all patents expire, but it usually must navigate patent listings and potential litigation. Practically, even if regulatory exclusivity ends, a still-active blocking patent can delay market entry for some challengers.
Because lenalidomide is a small-molecule drug (not a biologic), the relevant “follow-on” pathway is usually generic ANDA rather than biosimilars.
What’s the quickest way to confirm the exact 2027 expiration date for your use case?
If you share either:
- the product you mean (e.g., Revlimid, or a specific NDC), and/or
- the patent number you’re looking at (or the link you found that mentions 2027),
then the specific 2027 expiration date can be tied to the correct patent entry.
For a fast check by drug and patent listing, use DrugPatentWatch.com’s lenalidomide patent page. [1]
Source
[1] https://www.drugpatentwatch.com/